Niet gecategoriseerd

19 August 2025 Single-domain antibodies (sdAbs) appear to be excellent targeting molecules for Chimeric Antigen Receptor (CAR)-T cell therapies! This has also nicely been summed up by Guo and Xi (link in comments). CAR-T cells are engineered T cells that express a Chimeric Antigen Receptor (CAR) on their surface. This CAR allows the T cell to recognize and bind to a specific antigen on cancer cells. Although CAR-T has been a breakthrough and has already made a tremendous impact in the clinic for blood cancers, there are still some hurdles to overcome for solid cancers. In the first generations, the antigen-binding domain of the various CARs consisted of single-chain Fv fragments, which are fusion proteins of the variable domains of … Read more

14 July 2025 Last Friday we officially received the keys to our new state-of-the-art laboratory and office space on the 12th floor of Plus Ultra Utrecht, provided by Kadans Science Partner. We remain in the heart of the Utrecht Science Park, surrounded by a lot of knowledge, the hospital and a great industrial eco-system, but in a highly inspiring environment which stimulates innovation, this move reflects a significant step in the professionalization of our organization. Situated at the heart of the Dutch life science ecosystem, our new location supports our ambition to expand, collaborate, and innovate, which is further stimulated by entering the Kadans community including all Plus Ultra tennants spread over the life science hotspots of the Netherlands and … Read more

01 July 2025 A decade ago, the groups of Lukas Kapitein at Universiteit Utrecht University and Helge Ewers at Freie Universität Berlin showed that superresolution imaging with antibodies can be enhanced by using smaller probes like single-domain antibodies (sdAb). For example, the resolution of single molecule localization microscopy (SMLM) images of Tubulin could be substantially improved by using anti-tubulin sdAbs. QVQ now offers this anti-tubulin sdAb as purified recombinant protein for research purposes (product Q128c). Q128c has an unpaired thiol in its C-terminal tag for directional labelling.QVQ can deliver Q128c either as naked sdAb or conjugated to a fluorophores for normal and super resolution imaging.

17 June 2025 We are happy to share this recent publication resulting from a collaborative effort between Vrije Universiteit Amsterdam (VU Amsterdam), Amsterdam UMC, and QVQ Holding BV. This study showcases the potential of functionalized single-domain antibodies (sdAbs) in biomedical research and therapeutic development. By utilizing different fluorescent and luciferase-fused sdAbs, we were able to monitor the presence of higher-order clusters of CXCR4 on leukemic cells. These basal clusters could be disrupted by some small molecules, but also by our sdAb Q85 (VUN401). Interestingly, such disruption revealed that CXCR4 clusters actually drive oncogenic signaling and that targeting such clusters holds therapeutic potential. At QVQ, we are excited about the expanding possibilities of sdAbs – not only for targeting CXCR4, but … Read more

11 June 2025 We are proud to announce that QVQ, in collaboration with the Virology group of Universiteit Utrecht (Utrecht University), has won the competitive P3Dx Pandemic Preparedness by Pathogen Detection Innovation Challenge Tender from TNO. Our joint proposal, called QuickPan, stood out from eleven strong submissions and we’re thrilled to move forward with our innovative approach for super fast reagent-development for lab-independent, decentralized testing. Our technology is built on cutting-edge synthetic antibody libraries, enabling fast detection reagent identification. We believe it holds great potential for fast, scalable and flexible diagnostics. We look forward to be part of the P3Dx ecosystem and work together with other teams on strengthening diagnostic capabilities for future pandemics.

10 June 2025 Antibody Engineering & Therapeutics Europe 2025 is just around the corner — and QVQ will be there! We’re proud to have Edward Dolk and Raimond Heukers representing us at one of the leading events in antibody innovation. With 80+ expert speakers and over 300 attendees from across the globe, AE&T is a chance to connect directly with those that shape the future of antibody research, engineering, and therapeutic development. 🔬💡 📍 Where: Basel, Switzerland📅 When: June 10–12, 2025 Edward and Raimond are looking forward to exchanging ideas, discussing the latest technology and implementing these innovations in the next projects with QVQ 👋 Attending the event? Don’t be a stranger!Reach out to Edward or Raimond here on LinkedIn, … Read more

03 June 2025 It is THE conference dedicated to the smallest antibody fragment class, also referred to as VHH, sdAbs or nanobodies (trademark Sanofi). We would like to welcome you to mingle with sdAb-experts from industry and academia in the fantastic city of Utrecht in September.

27 May 2025 QVQ offers the production and purification of single-domain antibodies (sdAbs or VHHs) and VHH-based fusion proteins, using a range of expression systems including E. coli, S. cerevisiae, and ExpiHEK cells. Recombinant antibodies play a fundamental role in molecular biology, biotechnology, and pharmaceutical R&D. With the flexibility to express sdAbs in bacterial, yeast, or mammalian cells, we tailor our approach to meet the specific needs of each application. We’re proud to have expanded our capabilities with the addition of ExpiHEK cell-based expression—providing an optimal environment for proper folding and functionality of VHH and VHH-Fc proteins in particular. This enhancement supports our mission to deliver high-quality VHH-based molecules in a cost- and time-efficient manner. Partnering with QVQ means gaining … Read more

20 May 2025 Next week, Matti Pronker will be in Groningen for the FEBS Advanced Lecture Course: Emerging Insights from Structural Biology into Molecular Mechanisms of Diseases, where he will join researchers from around the world to discuss the latest developments in structural biology. Matti will give a presentation on 30 May during Session 5: Academia Meets Industry, sharing recent results in structural biology and protein engineering. He will also be available to discuss the latest in silico protein design developments at QVQ. Will we see you there?

30 April 2025 Next week, one of our scientists, Stephanie Anbuhl, will join the Trippenhuis meeting in Amsterdam. At this annual meeting of the Dutch Society of Cell Biology (DCSB), Stephanie will give a talk about applications of functionalized sdAbs for the detection of GPCRs. Will you join as well? Let’s have a chat!

29 April 2025 On May 28, 2025, you can find us at the BCF Career Event at Jaarbeurs Utrecht – the leading career fair for anyone in life sciences, chemistry, food, and pharma. Are you exploring new opportunities or just curious about who we are and what we do?Make sure to stop by our booth!We’re excited to connect with talent and explore how we can grow together.

22 April 2025 We are thrilled to announce that the French Ministry of Higher Education, Research and Innovation has granted a favorable opinion for our Research Tax Credit (CIR) application.This approval is valid for the next three years, retroactive to 2024 and extending to 2026. As a result, our customers can now benefit from a tax credit for our R&D support, covering up to 30% of the amount spent. At QVQ, we offer services that qualify for inclusion in a CIR file under certain conditions, ensuring that our customers can take full advantage of this valuable opportunity.